SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation

Immunocompromised patients, including HSCT recipients, may have a poor prognosis after contracting COVID-19 due to the absence of a pathogen-specific adaptive immune response. One of the possible options for severe COVID-19 treatment may be the transfusion of hyperimmune SARS-CoV-2 convalescent plas...

Descripción completa

Detalles Bibliográficos
Autores principales: Balashov, Dmitry, Trakhtman, Pavel, Livshits, Anna, Kovalenko, Irina, Tereshenko, Galina, Solopova, Galina, Petraikina, Elena, Maschan, Alexei, Novichkova, Galina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604030/
https://www.ncbi.nlm.nih.gov/pubmed/33153902
http://dx.doi.org/10.1016/j.transci.2020.102983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604030/
https://www.ncbi.nlm.nih.gov/pubmed/33153902
http://dx.doi.org/10.1016/j.transci.2020.102983

Ejemplares similares